The QualityStocks Daily Wednesday, September 8th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(KDMN) $9.0700 +71.13%

OTCtipReporter(HBIS) $1.7000 +30.77%

SmallCapRelations(ISWH) $1.5500 +26.02%

The QualityStocks Daily Stock List

PetVivo Holdings (PETV)

EmergingStockPlays, PennyStocks24, ExclusiveStockPick, VipStockReports, SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, Bull Trends, Pumps and Dumps, QualityStocks, Jet-Life Penny Stocks, Penny Pick Insider, Penny Stocks VIP, Equity Observer, Wall Street Mover, Daily Stock Motion, PoliticsAndMyPortfolio, Planet Penny Stocks, PennyStockProphet, Penny Stocks Profile, PennyStockShark, Penny Pick Finders, OTCBB Journal, Michael Stone, HotStockProfits, Growing Stocks Reports, First Penny Picks, Featured PS Report, Epic Stock Picks, DSR News, Club Penny Stocks Network, Buzz Stocks, MajorPennyStocks, Wallstreetbuzz, Research Driven Alerts, Research Driven Investor, Stock News Now, Value Penny Stocks, Trading Wall St, SuperStockTips, Super Nova Stock Picks, Fortune Penny Stocks, FOX Penny Stocks, The Lotto Pick, Greenbackers, Super Hot Penny Stocks, Hot Stock Profits, Super Hero Stocks, InvestorSoup, JackpotStock Picks, Goldman Small Cap Research, TopPennyStockMovers, StocksImpossible, USA Market News, LuckyStockPicks, Email Stock Picks, Damn Good Penny Picks, Wallstreet Profiler, WePickPennyStocks, Winning Penny Stock Picks, Breaking Bulls, Blaque Capital Stocks, Beacon Equity Research, AwesomeStocks, EpicVIP Group, Penny Stock Newsletter, Psycho Penny Stocks, PREPUMP STOCKS, RisingPennyStocks, SecretStockPromo, SixFigureStockPicks, SMS Penny Picks, PennyStock PayCheck, PennyStock MarketBulls, PennyPickAlerts, PennyDoctor, Xtreme Stock Picks, Ascending Stocks, Joe Penny Stocks, Penny Stock Pick Alert and Penny Stocks Finder reported earlier on PetVivo Holdings (PETV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PetVivo Holdings Inc. (NASDAQ: PETV) is a biomedical device and veterinary biotech firm that is focused on the licensing and commercialization of biomaterials and medical devices used to treat ailments and afflictions in companion animals like horses and dogs.

The firm has its headquarters in Minneapolis, Minnesota and was incorporated in 2009, on March 31st by John F. Dolan and John Lai. It serves consumers in the state of Minnesota and the United States at large.

PetVivo Inc., which is the company’s operating subsidiary, is involved in the acquisition and adaptation of human biomedical products and technology for commercial sale in the veterinary market to treat pets and other animals which suffer from painful ailments like arthritis. The company’s other subsidiary, Gel-Del Technologies Inc., has concluded a pivotal clinical trial which used their thermoplastic biomaterials as a dermal filler for cosmetic applications in humans.

The enterprise’s product pipeline is made up of more than 15 therapeutic devices for human and veterinary clinical applications. These include VD-04, which has been developed to treat urinary incontinence; VD-06 and VD-02, which have been developed for osteoarthritis management. Its lead product is an intra-articular joint injection dubbed Kush, which contains patented, gel-like biomaterials. It is indicated for the treatment of lameness and osteoarthritis in horses and dogs and is usually administered by veterinarians.

The company recently appointed a new national director of sales who has extensive experience in distribution and manufacturing in the animal health industry. This move will be good for the company, whose objective for success is growing its sales.

PetVivo Holdings (PETV), closed Wednesday's trading session at $3.27, off by 3.8235%, on 333,745 volume with 1,598 trades. The average volume for the last 3 months is 331,131 and the stock's 52-week low/high is $1.40799999/$17.00.

Cyanotech Corporation (CYAN)

Wall Street Resources, StockOodles, StreetInsider, MarketBeat, Trade of the Week, Investors Alley, Promotion Stock Secrets, StockMarketWatch, Dynamic Wealth Report, MarketClub Analysis, Daily Profit, SmallCapVoice, StreetAuthority Daily, TopStockAnalysts, TradingAuthority Daily and QualityStocks reported earlier on Cyanotech Corporation (CYAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyanotech Corporation (NASDAQ: CYAN) is focused on cultivating, producing and selling natural products derived from microalgae for the international human and health nutrition markets.

The firm has its headquarters in Kailua-Kona, Hawaii and was incorporated in 1983 by Gerald R. Cysewski. It serves consumers around the globe.

The company sells its products in bulk form to distributors, formulators and manufacturers in the health foods and nutritional supplements markets; directly to consumers; and also as packaged consumer products through online channels and retailers. It produces its algae in Hawaii and manufactures the finished products in California and Hawaii. The firm derives most of its revenue from the U.S. and from packaged products.

The enterprise’s products include a nutrient-rich dietary supplement dubbed Hawaiian Spirulina Pacifica, which is used as a source of antioxidant carotenoids, as well as for its cardiovascular benefits, strengthened immune system and extra energy. It also produces a dietary antioxidant known as BioAstin Hawaiian Astaxanthin, which is used as a dietary ingredient to maintain and support the body’s natural inflammatory response, support immune, joint and eye health and improve the skin. The ingredient is usually used as a human dietary supplement. In addition to this, the enterprise offers phycobiliproteins dubbed Sirulina Pacifica, which are florescent pigments utilized in the immunological diagnostics market.

The global algae-based animal feed and ingredients market is expected to grow by over $700 million between 2021 and 2025. The company’s involvement in the market positions it for growth as the adoption of microalgae in the food supplement and nutraceuticals industry grows.

Cyanotech Corporation (CYAN), closed Wednesday's trading session at $3.02, off by 2.4233%, on 136,394 volume with 307 trades. The average volume for the last 3 months is 136,394 and the stock's 52-week low/high is $2.36999988/$6.28999996.

Gold Resource Corporation (GORO)

StreetInsider, Wall Street Grand, Wyatt Investment Research, MarketBeat, QualityStocks, Streetwise Reports, TradersPro, StockMarketWatch, InvestorPlace, MarketClub Analysis, BUYINS.NET, Street Insider, Greenbackers, Rick Saddler, Dynamic Wealth Report, Short Term Wealth, FeedBlitz, Top Pros' Top Picks,, TheStockAdvisor, TraderPower, Dividend Opportunities, OTC Press, MonsterStocksPicks, DrStockPick, Money and Markets, PennyOmega, StockHotTips, Investor Update, Money Morning, The Street, WealthMakers, Wealth Insider Alert, WallStreetGrand, Trading Tips, TopStockAnalysts, Standout Stocks, The Tycoon Report, Profit Confidential, Super Stock Investor, StreetAuthority Daily, StockOodles, Zacks, Stock Stars, SmallCapVoice and Tiny Gems reported earlier on Gold Resource Corporation (GORO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gold Resource Corporation (NYSE American: GORO) (FRA: GIH) (ETR: GIH) is a mining firm that is engaged in the exploration, development, production and sale of silver and gold in the United States and Mexico.

The firm has its headquarters in Denver, Colorado and was incorporated in 1998, on August 24th by William W. Reid and David C. Reid. The firm serves consumers in the both the United States and Mexico.

The company also explores for zinc, lead and copper deposits, as well as doré containing silver and gold. It operates through the Corporate and other, Nevada and Mexico segments. The company targets low capital expenditure projects with potential to generate high returns on capital. Its mineral properties are categorized into exploration properties, development properties and operating properties.

The enterprise holds 100% interest in 6 properties, including 4 exploration properties and 2 operating properties, through its Don David Gold Mexico S.A. subsidiary. Its exploration properties include the Rey property, Fuego property, Chamizo property and Margaritas property, while its operating properties comprise of the Alta Gracia project and the Aguila project. Both operating projects are located in the state of Oaxaca, Mexico. The Aguila project is made up of 18 mining concessions that cover an area of about 24,400 hectares.

The company is focused on strengthening its senior leadership team, having recently appointed a new chief operating officer. This move adds to the expertise necessary for unlocking the value of the company’s assets and is bound to have a positive influence on efficiency and overall growth.

Gold Resource Corporation (GORO), closed Wednesday's trading session at $1.78, up 4.0936%, on 1,122,259 volume with 4,040 trades. The average volume for the last 3 months is 1.122M and the stock's 52-week low/high is $1.57000005/$4.06150007.

Lannett Company Inc. (LCI)

StreetAuthority Daily, TopStockAnalysts, InvestorPlace, Investing Lab, Zacks, StreetInsider, Darwin Investing Network, Investing Signal, VectorVest, MarketClub Analysis, The Street, Traders For Cash Flow, Barchart, ProfitableTrading, Schaeffer's, The Weekly Options Trader, StockMarketWatch,, Money Morning, Dividend Opportunities, Short Term Wealth, MarketBeat, QualityStocks, Trader Prep, BUYINS.NET, Buttonwood Research, TopPennyStockMovers, SmallCapVoice, PoliticsAndMyPortfolio, CrashTrade, CRWEPicks, Average Joe Options, BestOtc, Investopedia, Trades Of The Day, Investors Alley, GorillaTrades, DrStockPick, TraderInsight, StockHotTips, CRWEFinance, Daily Dividends, CRWEWallStreet, The Best Newsletters, One Hot Stock, PennyOmega, PennyStockLive, PennyToBuck,, Hit and Run Candle Sticks, GreatStockPix, MarketWatch, Weekly Wizards, Wealthpire Inc., Trading Concepts, TradersPro Morning, Traders For Wealth, Super Stock Picker, MarketTamer, Rick Saddler, Investing Daily, Agora Financial, MarketDeal, Louis Navellier, Kiplinger Today, InvestorsUnderground, Investment House and Small Cap Firm reported earlier on Lannett Company Inc. (LCI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lannett Company, Inc. (NYSE: LCI) (FRA: LN5) is engaged in the development, manufacture, packaging, marketing and distribution of generic versions of brand pharmaceuticals in the U.S.

The firm has its headquarters in Trevose, Pennsylvania and was incorporated in 1942. It operates through the generic pharmaceuticals segment and serves consumers in the United States.

The company is party to development and supply agreements with RivoPharm, Elite Pharmaceuticals, Dexcel Pharma, HEC Group of Companies and Summit Bioscience LLC, among other firms. It sells its products to health maintenance organizations, governmental entities, hospital buying groups, managed care organizations, mail order pharmacies, private label distributors, chain drug retailers, drug wholesalers, generic pharmaceutical distributors and other pharmaceutical companies.

The enterprise’s primary products include analgesic sedatives, dermatological preparations, antacids and antifungals like Methylphenidate Hydrochloride ER stimulants, Metolazone tablets, Sumatriptan Nasal spray, Omeprazole capsules, Verapamil SR tablets, Fluphenazine tablets and Levothyroxine Sodium tablets. It provides solid oral and extended releases dosage forms of drugs which address various therapeutic areas, as well as injectable, soft gel buccal, sublingual foam, patch and ophthalmic dosages. In addition to this, the enterprise offers its products for a range of medical indications, including urinary, cold/cough/allergy/respiratory, migraine, infectious disease, gastrointestinal, central nervous system and cardiovascular indications.

The company recently entered into an agreement to be the sole distributor of generic Spiriva Handihaler in the United States, which brings the total of large durable assets in the company’s pipeline to no less than five. This agreement will not only bring in additional revenue into the firm but also extend its consumer reach, which will be good for its growth.

Lannett Company Inc. (LCI), closed Wednesday's trading session at $3.33, off by 2.0588%, on 1,051,955 volume with 4,081 trades. The average volume for the last 3 months is 773,720 and the stock's 52-week low/high is $3.25/$10.6999998.

Medavail Holdings (MDVL)

MarketBeat reported earlier on Medavail Holdings (MDVL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Medavail Holdings Inc. (NASDAQ: MDVL) (FRA: 73M0) is a tech-enabled pharmacy firm that is engaged in the provision of pharmacy services.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2007, on April 11th. It serves consumers in Canada.

The company operates through the pharmacy technology segment and the retail pharmacy services segment. It sells and licenses its proprietary software and hardware to retailers, health systems and other industry consumers who would like to leverage their own pharmacy operations to bring greater service, automation and convenience to their members and patients. The company also assists patients in optimizing drug adherence, leading to better health outcomes.

The enterprise is involved in the development and commercialization of a pharmacy, kiosk, mobile application and drive-thru solution. Its primary technology and product is a prescription dispensing system which is customer-interactive and controlled by the pharmacist, dubbed MedCenter. This technology is akin to a prescription-dispensing ATM or a pharmacy in a box. The MedCenter enables live pharmacist counselling through 2-way audio-video communication. The enterprise also operates a full-service retail pharmacy known as SpotRx, which uses its automated pharmacy technology. In addition to this, it develops and commercializes advanced nutrition products that boost muscle health and performance.

The firm recently entered into a strategic arrangement with Zipdrug, which selected SpotRx as its primary partner. The move will allow SpotRx to serve consumers in the Tucson area, which will not only extend the firm’s consumer reach but also afford it more expansion opportunities. This may in turn boost the firm’s growth.

Medavail Holdings (MDVL), closed Wednesday's trading session at $3.41, off by 2.0115%, on 269,247 volume with 2,211 trades. The average volume for the last 3 months is 269,247 and the stock's 52-week low/high is $2.81999993/$20.7900009.

Eco Depot, Inc. (ECDP)

StockRockandRoll, StockLockandLoad,, PennyStocks24,, Michael Stone, Research Driven Investor, Growing Stocks Reports, Xtreme Stock Picks, SmallCapInvestorDaily, Super Hero Stocks, RagingStock Bull, Pumps and Dumps, JackpotStock Picks, PennyStock Tweets, PennyStock PayCheck, PennyStock MarketBulls, PennyDoctor, Wallstreet Profiler, Blaque Capital Stocks, The Observer, InvestorTrendz, Penny Stocks VIP, Penny Stock Mobsters, Stockgoodies, Penny Pick Insider, Email Stock Picks, Daily Stock Motion, SuperStockTips, Darth Trader, Wall Street Beauties, Penny Stocks On Steroids, Beacon Equity Research, Penny Stocks Finder, InvestorSoup, MassiveStockProfits, StockMarketIntel, POSstocks, PremiereStockAlerts, MajorPennyStocks, QualityStocks, OTCtipReporter, Penny Stock Craze, Stock Preacher, WINNINGOTC, smartOTC, StockProfessors, The Stock Psycho, SizzlingStockPicks, PennyStockScholar, Equity Observer, Penny Picks, ResearchOTC, Research Driven Alerts, Jet-Life Penny Stocks, OtcShortReport, Damn Good Penny Picks, BestDamnPennyStocks, DSR News,, LuckyStockPicks, Liquid Tycoon, Liquid Pennies, Joe Penny Stocks, EpicVIP Group, FOX Penny Stocks, HotStockProfits, HEROSTOCKS, Greenbackers, Epic Stock Picks, SmallCap Fortunes, Winning Penny Stock Picks, WePickPennyStocks, WallstreetsHotteststocks, Wallstreetbuzz, VIP STOCK ALERTS, Value Penny Stocks, USA Market News, Top Stock Picks, TheNextBigTrade and SuperHotPennyStocks reported earlier on Eco Depot, Inc. (ECDP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Eco Depot, Inc. acquires, manages, as well as develops eco-friendly real estate assets and consumer brand products. The Company’s focus is to provide investments, funding, and support for acquisitions, start-ups, entrepreneurs, and green companies committed to protecting the environment. A Nevada company, and founded in 2004, Eco Depot lists on the OTC Markets. The Company is headquartered in Las Vegas, Nevada.

Currently, Eco Depot is focused on commercializing Bronya Climate Shield. This is a versatile thermal insulation paint capable of increasing energy efficiency and decreasing carbon emissions.

Bronya Climate Shield™ is a multi-purpose liquid insulation. It can be applied on any surface, indoors and outdoors, at temperatures of -60 °C up to +200 °C. Bronya Climate Shield is a cost-effective Do-It-Yourself (DIY) product with thermal conductivity of 0,001 W/m Celsius. It is proven to lessen energy costs by up to 40 percent and labor costs by 70 percent. In addition, the product provides insulation lasting from 10 to 30 years, depending on the application.

Eco Depot previously announced it completed labs to meet the ISO Fire Retardant Standards for Nordic Structures prefabricated I-Joist building products manufacturing. Lab results from studies conducted by FPInnovations, sponsored by Nordic Structures, as a potential economic advantage to fire proofing OSB manufactured I-Joists, have marked Bronya Climate Shield Thermal Liquid Insulation as "Promising" and functionally meeting ISO minimum Fire Retardant Standards. The lab results will be made available in a supplementary filing. They are also available by request at Eco Depot corporate.

Eco Depot, Inc. (ECDP), closed Wednesday's trading session at $0.98, up 24.8249%, on 134,360 volume with 162 trades. The average volume for the last 3 months is 134,360 and the stock's 52-week low/high is $0.0126/$5.57999992.

Kadmon Holdings (KDMN)

MarketClub Analysis, StockMarketWatch, Kiplinger Today, MarketBeat,, TradersPro, InvestorPlace, StreetInsider, Barchart, BUYINS.NET, The Online Investor, Wealth Insider Alert, The Street, Trades Of The Day, Daily Trade Alert and QualityStocks reported earlier on Kadmon Holdings (KDMN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kadmon Holdings Inc. (NASDAQ: KDMN) (FRA: KDF) is a biopharmaceutical firm that is focused on the discovery, development and commercialization of small molecules and biologics which are mainly used to treat fibrotic and inflammatory ailments.

The firm has its headquarters in New York and was incorporated in September 2010 by Steven N. Gordon. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry and serves consumers in the U.S.

The company is party to a strategic license and collaboration agreement with Dyax Corp. and another agreement with Nano Terra Inc. It is focused on addressing disease areas of significant unmet medical needs.

The enterprise’s product pipeline comprises of an anti-PD-L1/IL-15 fusion protein dubbed KD033 indicated for cancer treatment; an oral rho-associated coiled-coil kinase (ROCK) inhibitor known as KD045 developed to treat fibrotic ailments; and an orally administered ROCK2 inhibitor dubbed KD025 (Belumosudil), which is currently undergoing a phase 2 clinical trial evaluating its effectiveness in treating systemic sclerosis, which is characterized by vascular damage, fibrosis and chronic inflammation as well as chronic graft-versus-host disease. In addition to this, the enterprise also develops trientine hydrochloride capsules known as CLOVIQUE for treating Wilson’s disease and Tesevatinib, indicated for the treatment of autosomal dominant polycystic kidney disease.

The FDA recently approved the firm’s KD-025 formulation for the treatment of chronic-graft-versus-host disease, which brings the formulation one step closer to the market. This approval will help bring in more investors into the firm.

Kadmon Holdings (KDMN), closed Wednesday's trading session at $9.07, up 71.1321%, on 146,648,929 volume with 176,990 trades. The average volume for the last 3 months is 146.649M and the stock's 52-week low/high is $3.14499998/$9.1999998.

Dream Homes & Development Corporation (DREM)

QualityStocks and PennyDoctor reported earlier on Dream Homes & Development Corporation (DREM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dream Homes & Development Corporation is a fully integrated real estate company listed on the OTC Markets’ OTCQB. Licensed new home builders and general contractors, Dream Homes is building, raising, renovating and reconstructing homes up and down the New Jersey shore area. Established in 2009, and a full-service construction company, Dream Homes & Development is based in Forked River, New Jersey.

Dream Homes & Development is equipped to complete all facets of a building project. This includes design, architectural, engineering, and construction. The Company is a full-service building and development enterprise that operates chiefly in the coastal areas of New Jersey.

Dream Homes & Development provides an array of services and products. These include land development and approvals, infrastructure installation, new single and multi-family construction, engineering & structural design, soil studies, architectural and design/build capabilities, and construction management services.

Services and products provided additionally include general contracting of all residential single and multi-family construction, helical and timber pile installation, masonry foundations and concrete work of all varieties, management of home elevation and moving projects and complete finish requirements for all interior construction.

Dream Homes has successfully completed over 1,500 new homes and more than 200 elevation projects. The Company is contracted to develop and construct a 60-unit town home development in Lacey Township, New Jersey over the next two years valued at $12 to $14 million.

At present, Dream Homes & Development has a number of new home properties under contract and in development. These new developments include 13 single family homes, 58 townhomes and 68 waterfront townhomes, all in the Ocean County region of New Jersey.

Dream Homes & Development has its new Modular Division in Point Pleasant, New Jersey. The office and showroom in Point Pleasant allows Dream Homes to better serve the northern Ocean/southern Monmouth region of New Jersey. It complements the main office in Forked River. The showroom offers a complete kitchen, bath, flooring, as well as finish design center. The new Design Center in Point Pleasant has led to growth in modular traffic and sales. In addition, it has facilitated and increased client selections throughout the Company’s entire region.

Dream Homes & Development has completed the acquisition of Premier Modular Homes. Premier has a 23-year record of accomplishment serving southern Ocean County with a focus on Long Beach Island. Dream Homes has acquired a substantial portion of the assets of Premier Modular Homes, located in Little Egg Harbor, New Jersey. The acquired assets include physical and intellectual property (IP), such as phone numbers, web site, use of the Premier Modular Home name, equipment, vehicles and trailers. Furthermore, the Company leased the physical premises. This includes the office, showroom, garage, as well as yard space.

Dream Homes & Development Corporation (DREM), closed Wednesday's trading session at $0.0749, up 76.2353%, on 69,710 volume with 2 trades. The average volume for the last 3 months is 69,710 and the stock's 52-week low/high is $0.030999999/$0.085.

Demand Brands (DMAN)

QualityStocks, OTCPicks, The Street, CRWEFinance, CRWEPicks, CRWEWallStreet, Daily Markets, DrStockPick, BestOtc, InvestorPlace, WiseAlerts, PennyOmega, StockHotTips, StreetInsider, Trades Of The Day and Dynamic Wealth Report reported earlier on Demand Brands (DMAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Demand Brands Inc. (OTC: DMAN) is an investment holding firm that is engaged in the provision of marketing solutions.

The firm has its headquarters in California and was incorporated in 1996, on October 22nd. It serves consumers across the globe and operates under the financials industry, in the financial services industry, under the asset management sub-industry.

The enterprise is centered on partnerships, strategic acquisitions and joint ventures with a particular interest in food, CBD, marijuana edibles and hemp, as well as related technology and educational industries.

The company promotes healthy lifestyles for pets, children, women and men and mainly operates in the hemp, cannabis edibles, health and wellness, superfoods and cannabidiol sectors. Its brands include CoCos Pure, Oil of Sunshine, Canadian Organic Popcorn, Weedies Edibles and Infusional. The company markets beverages, vapes, oils and edible products under these brands. This is in addition to engaging in the development of drone program technologies and electro-seismic applications for the energy industry. The company, through Pacific Technology Group Inc., its wholly owned subsidiary, looks for and invests in emerging technology sector businesses.

Demand Brands, through its wholly owned subsidiary, recently entered into an agreement with Viride Research Fund. This move will allow Demand to acquire Viride and other assets which will be marketed under the Lucky Chief brand. The assets include its interests in a dispensary and extraction lab as well as its THC genetics library. Viride is a leading firm in the global marijuana industry. Acquiring synergistic assets will facilitate the advancement of a vertically integrated marijuana-focused consumer packaged business, which may bring in hefty returns and investments.

Demand Brands (DMAN), closed Wednesday's trading session at $0.0184, up 26.8966%, on 7,360,397 volume with 170 trades. The average volume for the last 3 months is 7.36M and the stock's 52-week low/high is $0.002099999/$0.0434.

Globalstar (GSAT)

Schaeffer's, StreetInsider, StockMarketWatch, The Street, Real Pennies, Wall Street Resources, Market Report, Barchart, BUYINS.NET, QualityStocks, Daily Trade Alert, MarketBeat, InvestorPlace, StockTradersHQ, PennyStocks24, Stock Analyzer,, DrStockPick, CRWEWallStreet, CRWEFinance, BestOtc, StockEgg, PennyOmega, PennyToBuck, SmallCapVoice, StockHotTips, PennyTrader Publisher, BullRally, AllPennyStocks, Penny Invest, HotOTC, CoolPennyStocks, Promotion Stock Secrets, Penny Stock Rumble, The Weekly Options Trader, Street Insider, TradersPro, TopPennyStockMovers, Hit and Run Candle Sticks, Greenbackers, Fast Money Alerts, The Bull Report, Direction Alerts, PoliticsAndMyPortfolio, CRWEPicks, Investor Guide, Top Stock Picks, Total Wealth, Wall Street Wolves, WealthMakers, TheSUBWAY, Penny Stock General, Shiznit Stocks, SmallCap Network, Smart Penny Stocks, PennyStockVille, SmarTrend Newsletters, Stock Beast, StockRich, Stock Fortune Teller, Investing Futures, Penny Sleuth, Stock Market Watch, Stock Rich, Stock Shock and Awe, MadPennyStocks, StockOodles, Zacks and PennyInvest reported earlier on Globalstar (GSAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Globalstar, Inc. (NYSE American: GSAT) (FRA: P8S) is a leading supplier of customizable IoT solutions to clients around the world in sectors like oil and gas, government, emergency response, outdoor recreation, commercial maritime, forestry, agriculture, and transportation.

The firm is a pioneer in the field of providing mobile satellite data and voice services. The solutions the company provides allow people to be connected to their devices thereby enabling businesses to streamlines their processes even if those businesses operate in areas without cellular network coverage.

Globalstar’s portfolio of products includes the widely acclaimed SmartOne asset tracking range of products; the SPOT range of products geared at facilitating personal safety, messaging and emergency response; plus commercial IoT satellite transmitters. All these products are supported on the company’s cloud-based mapping solution called SPOT My Globalstar. This product range is made by the company’s subsidiary called SPOT LLC.

In mid-April 2021, Globalstar’s fully-owned subsidiary Globalstar do Brasil partnered with Cisa Trading to take asset management solutions to the oil and gas sector in Brazil. This partnership is already yielding results as Cisa Trading required tracking and satellite monitoring for a shipment of 4,400 containers, and Globastar is providing the needed services for each of those containers. The Cisa Trading shipment is likely to be the first of many such deals which Globalstar will secure in the Brazilian oil and gas market.

Additionally, Globalstar agreed a deal with with Ceres Tag, an Australian animal tracking services provider. As a result of that deal, Globalstar has already made a shipment of 10,000 units and many other large shipments are expected as the company is set to consolidate its footprint in the animal tracking sector as demand for securing food supply chains grows.

All these contracts mean that the foreseeable future of the company is bright, and investors are likely to see a significant growth in share value as the company grows and deepens its footprint in various industries and markets.

Globalstar (GSAT), closed Wednesday's trading session at $2.69, up 29.9517%, on 289,993,797 volume with 373,490 trades. The average volume for the last 3 months is 289.994M and the stock's 52-week low/high is $0.291999995/$2.98000001.

Creative Medical Technology Holdings Inc. (CELZ)

We reported earlier on Creative Medical Technology Holdings Inc. (CELZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings (OTC: CELZ) entered into definitive agreements with accredited institutional investors for gross proceeds of approximately $3,788,000. The definitive agreements provide for the private placement of 15% original issue discount senior notes (“notes”) in the aggregate principal amount of approximately $4,456,000; the principal amount of the notes will be due on Feb. 11, 2022. The company has also agreed to issue to the investors unregistered warrants for the purchase of 157,184,354 shares of common stock. Each warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.02835 for a period of five years from the date of issuance. Roth Capital Partners acted as the sole placement agent for the offering, which closed on Aug. 11, 2021.

To view the full press release, visit

Creative Medical Technology Holdings is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For more information, please visit

Creative Medical Technology Holdings Inc. (CELZ), closed Wednesday's trading session at $0.0229, off by 11.9231%, on 29,731,649 volume with 662 trades. The average volume for the last 3 months is 29.732M and the stock's 52-week low/high is $0.0013/$0.129999995.

F45 Training Holdings Inc. (FXLV)

The Street, StocksEarning and MarketBeat reported earlier on F45 Training Holdings Inc. (FXLV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

F45 Training Holdings (NYSE: FXLV) has closed its initial public offering of 21,851,944 shares of its common stock, including a partial exercise of the over-allotment option granted to the underwriters consisting of 19,057,889 shares offered by F45 and 2,794,055 shares offered by certain selling stockholders. F45 secured gross proceeds of approximately $350 million, with each of the shares sold at the public offering price of $16.00. The shares began trading on the New York Stock Exchange under the symbol FXLV on July 15, 2021. Roth Capital Partners acted as co-manager for the offering.

To view the full press release, visit

F45 offers consumers functional 45-minute workouts that are effective, fun and community-driven. F45 utilizes proprietary technologies: a fitness programming algorithm and a patented technology-enabled delivery platform that leverages a rich content database of over 3,900 unique functional training movements to offer new workouts each day and provide a standardized experience across the company’s global footprint. For more information, please visit

F45 Training Holdings Inc. (FXLV), closed Wednesday's trading session at $14.23, up 0.211268%, on 260,935 volume with 3,877 trades. The average volume for the last 3 months is 260,935 and the stock's 52-week low/high is $12.9799995/$17.75.

The QualityStocks Company Corner

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

DSG Global (OTCQB: DSGT) today announced that the SUV ET5, rebranded as the Sport Electric Vehicle (“SEV”), has arrived in Montreal in time for the Montreal Electric Vehicle show. Slated to run from Sept. 17-19, 2021, the Montreal Electric Vehicle Show is the largest EV gathering in Canada and is set to attract the attendance of over 30,000 members of the media, industry professionals and consumers. Imperium Motors Canada President Christian Dubois will be showcasing Skyworth’s SEV in booth #807 at the event. “I am very excited to spend these three days of the salon in my hometown of Montreal and meet electric vehicles enthusiasts and journalists, as well as meeting many of the dealership applicants who have shown an interest in representing Imperium in Quebec,” Dubois said in the press release. The company will be accepting orders and deposits on the Imperium Motors SEV with expected deliveries beginning in the fourth quarter of 2021. In addition, the company will begin accepting online orders on all vehicles on or before this event. To view the full press release, visit

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.


Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Wednesday's trading session at $0.185, up 0.844917%, on 1,460,411 volume with 227 trades. The average volume for the last 3 months is 1.46M and the stock's 52-week low/high is $0.0251/$1.51999998.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, will host a stellar list of keynote speakers for is upcoming edtech event. The 2021 Sequire EdTech Conference is slated for Sept. 13, 2021, from 11:30 a.m.–5:30 p.m. ET. This year’s event features an impressive slate of main speakers, including Patrick Brothers, cofounder and co-CEO of HolonIQ, a global market intelligence platform for education; Gagan Biyani, cofounder of Udemy, an online education company; Ann Marie Sastry, CEO of Amesite, an award-winning artificial intelligence software company focused on improving learning; Barbie Brewer, chief people officer at Netflix and board member at Amesite; Mary Juhas, associate vice president at The Ohio State University; Julia Pugachevsky, education editor at Insider; and Jonathan Satchell, CEO of Learning Technologies Group, a global, fast-growing, full-service digital learning and talent management company. In addition to these keynote addresses, the one-day investor event will include presentations from more than 10 virtual work and learning companies. To register for the event, visit To view the full press release, visit

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $5.36, up 1.1321%, on 271,890 volume with 2,389 trades. The average volume for the last 3 months is 271,890 and the stock's 52-week low/high is $2.05999994/$7.28999996.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

  • The Happy Co.’s Transformation Challenge includes weekly, monthly prizes as well as five grand prize winners.
  • Fit & Happy Weight Loss System, available in Vanilla, Mocha and Birthday Cake flavors, includes filling shakes, Energy Caps and a calming nighttime Chill Drink.
  • Qualifying posts can be on public Facebook, Instagram, TikTok or Twitter pages.

Sharing Services Global (OTCQB: SHRG) subsidiary The Happy Co. has invited users of its Weight Loss System to share their transformation through social media — and be rewarded for looking better, feeling better and performing better ( The Happy Co.’s Transformation Challenge includes weekly and monthly prizes as well as five grand prize winners, who will receive $1,000 each.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed Wednesday's trading session at $0.1122, up 24.6667%, on 93,273 volume with 28 trades. The average volume for the last 3 months is 93,273 and the stock's 52-week low/high is $0.086350001/$0.477999985.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

The government is determined to replace the fossil fuel vehicles on the roads with zero-emission electric vehicles (“EVs”), so much so that President Joseph Biden recently announced that his administration was aiming to achieve 50% electric vehicle sales by 2030. Automakers are already on board, including EV startups and companies that have been around for a while, such as Ford and Mercedes. In addition, we are likely to see more than two dozen new EV models in the next few years. However, thanks to America’s inadequate public charging infrastructure, range anxiety and charging are among the most significant barriers to EV adoption in the country. The road trip test conducted by CNBC makes it abundantly clear that EV sector players such as Net Element (NASDAQ: NETE) and other stakeholders have their work cut out if they are to ensure that the inadequacy of charging facilities doesn’t slow down the uptake of EVs.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday's trading session at $9.93, up 1.8462%, on 809,931 volume with 3,640 trades. The average volume for the last 3 months is 809,148 and the stock's 52-week low/high is $5.57000017/$19.1499996.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

  • Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
  • The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
  • Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
  • Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is approaching the launch of its phase 2a clinical trial that will use synthetic psilocybin (a psychedelic drug derived from certain mushrooms) in combination with psychotherapy for a select class of overeating disorders.

Researchers have found that psilocybin, which is the hallucinogenic compound found in so-called magic mushrooms, has shown potential in treating various mental conditions, including anxiety, major depressive disorder and  addiction. With companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) engaged in psychedelic-based medicine development, opportunities for participating in clinical trials could soon present themselves to those interested.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.


Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Wednesday's trading session at $0.3459, up 0.552326%, on 48,051 volume with 25 trades. The average volume for the last 3 months is 48,051 and the stock's 52-week low/high is $0.322299987/$1.03999996.

Recent News

Simply Sonoma Inc.

The QualityStocks Daily Newsletter would like to spotlight Simply Sonoma Inc.

In a CBD market becoming ever more crowded, Simply Sonoma is preparing to launch a line of CBD products that is truly distinctive. The company, which is also in the midst of a SEC regulation CF offering, is creating unique medicinal hemp strains that are alternatives to traditional, chemically manufactured offerings. Specifically, the company is committed to providing products based on formulations driven by solid scientific research ( Simply Sonoma also works to educate consumers by providing relevant, timely information, including appropriate dosage levels. In addition, the company is looking beyond the traditional CBD offerings of gummies and tinctures, instead eyeing unique and different product options, such as CBD-infused organic apple juice and alcohol-free wine beverages. For more information or to invest in Simply Sonoma, visit the company’s website at

Simply Sonoma Inc. produces healthy CBD medicinals and beauty products for the environmentally conscious consumer. The company strives to create the best sustainably grown natural medicinal alternative products and is committed to minimizing its carbon footprint by powering operations off-the-grid using solar energy. Simply Sonoma is creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. The company believes in all-natural, organically sun-grown, plant-based medicinals, and it provides consumers with science-based education on CBD for disease and lifestyle needs.

Simply Sonoma is focused on being a leader in the industry for plant-based medicinal health and beauty products and partnering with like-minded organizations. The company strives to develop broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company believes in published, science-based trials and research with regard to its CBD creations.

Simply Sonoma is a different kind of natural company. From seed to sale, it owns or contracts the organic grow, extraction and product formulation operations. The company has been developing products since 2017 based on scientific research and data and has several ready to launch. Its nationally available organic CBD products employ the company’s own proprietary formulations.

For example, the company’s nonalcoholic CBD Pinot Noir beverage uses grapes specially grown for Simply Sonoma and is infused with CBD from the company’s farm. The company expects to generate revenue through national sales of its CBD products via e-commerce, as well as through a variety of chain stores, pharmacies and small businesses throughout the U.S.


Simply Sonoma has three tiers of products:

  1. Organic CBD formulations for consumer medicinal applications.
  2. Organic whole plant extracts of CBD and cannabinoids – providing the whole plant synergistic effect and giving a dose response for a variety of diseases.
  3. Organic extracts paired with traditional over-the-counter functionality, delivering all the benefits of traditional OTC products but the bulk product is organic and plant derived for a more natural healthy approach, minimizing synthetic chemical components and adverse effects.

An example of tier three would be the company’s sleep aid. Current over-the-counter and prescription sleep aids like benzodiazepines, antihistamines and sleeping pills disrupt normal sleep brain patterns including REM, resulting in abnormal sleep. CBD and cannabinoids have efficacy as sleep aids and do not disrupt the normal sleep cycle.

Depending on the application, the company’s products can be delivered via:

  1. Teas
  2. Pills
  3. Inhalers
  4. Skin patches
  5. Gummies
  6. Tablets
  7. Sublingual sprays
  8. Tinctures
  9. Topicals
  10. Juices

Simply Sonoma has partnered with Sonoma Biologics, a premium hemp cultivator that has completed considerable research on the scientific nature of hemp and cannabis, to grow proprietary medicinal strains specifically for the company. Additionally, Simply Sonoma is working with Organic Vineyards on the company’s antioxidant, alcohol free, CBD wine product, as well as its low carb, low sugar Pinot Noir CBD sparkling product. All partner companies are environmentally conscious, solar first and organic-equivalent. Simply Sonoma’s CBD products will contain less than 0.3% of THC.

Market Outlook

Simply Sonoma competes with numerous nondescript CBD companies in the market today. The company feels its major competitive advantage is its scientific staff and product formulation expertise. Simply Sonoma products are focused on four specific health, beauty and lifestyle markets, including sleep aids, joint pain, probiotics and skin health. The Market Data Forecast valued the global sleep aid market at an estimated $175 billion in 2020. The joint pain and anti-inflammatory market is forecast to be worth approximately $41 billion in 2026 by Persistence Market Research. The market for gut health and probiotic products is expected to hit $65 billion by 2023, according to Global Market Insights. Allied Market Research valued the global beauty and skin product market at $380 billion in 2019.

Management Team

Simply Sonoma’s dynamic team has a unique combination of experience that positions them well with the company’s wellness and lifestyle products in the CBD space.

Margaret C. Caracciolo is the CEO of Simply Sonoma. She has spent most of her career in biotechnology, in the areas of clinical research and financials. She has worked for notable biotech companies including Heartport, an innovator of heart therapies. She spent time at Aviron, supporting the development of its innovative nasal flu inoculation product, and Genitope, which created personal gene therapies. She has spent the last 10 years co-managing her family’s farm and vineyard and creating wines and other products from the farm’s organic gardens.

Angela Miller is Vice President of Operations at Simply Sonoma. She has extensive experience in cross line-of-business, global project management, and analysis from inception to post-go-live. She spent more than 20 years working at Oracle Corp. and Sun Microsystems Inc., where she obtained expertise in global products, team building, troubleshooting, and customer relations. She also worked seven years with Schwinn Cycling & Fitness, doing everything in the Fitness Division from project management to marketing and public relations.

Recent News


Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on Monday, Sept. 13, 2021. Interested institutional or retail investors should visit to register for the conference and may listen to the company’s presentation online at replay of the presentation will be available via the Investor Relations page of the company’s website. To view the full press release, visit

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.


R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Wednesday's trading session at $5.28, off by 6.2167%, on 437,157 volume with 2,546 trades. The average volume for the last 3 months is 437,157 and the stock's 52-week low/high is $2.60999989/$14.4099998.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

  • Investor appetite in Africa continues to be robust, attracting $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018
  • Agriculture makes up 23 percent of sub-Saharan Africa’s GDP and 60 percent of employment
  • Tingo directly benefits the African economy by helping farmers gain better prices for their crops
  • The company enables more efficient markets via greater distribution of agricultural products
  • Tingo directly provides an access point to technology for tens of millions of Africans
  • The company is expanding into fintech banking services for the mass market, providing access to financial services through Tingo Pay, its proprietary mobile wallet application

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.


Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Wednesday's trading session at $2.8, off by 6.6667%, on 797 volume with 7 trades. The average volume for the last 3 months is 797 and the stock's 52-week low/high is $1.50/$8.97999954.

Recent News

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF)

The QualityStocks Daily Newsletter would like to spotlight Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF).

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, has announced that it will featured at the upcoming H.C. Wainwright 23rd annual Global Investment Conference. The three-day conference is scheduled to begin Sept. 13 and runs through Sept. 15, 2021. MINDCURE president and CEO Kelsey Ramsden will present an overview of the company on Sept. 13, 2021, at 7 a.m. ET. The presentation will be available for interested viewers for 90 days following the conference. To view the presentation, visit To view the full press release, visit

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.


Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.


In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

Mind Cure Health Inc. (OTCQB: MCURF), closed Wednesday's trading session at $0.28, off by 3.0471%, on 78,585 volume with 40 trades. The average volume for the last 3 months is 78,585 and the stock's 52-week low/high is $0.253500014/$0.858399987.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company, recently launched version 2.0 of its Fan Pass livestream platform and completed several rebranding initiatives, including an updated corporate look and a new website. The rebranding announcement came on the heels of a recent interview in which Friendable CEO Robert A. Rositano Jr. discussed the company’s vision and plans, revenue and growth strategy and market opportunities. An article quotes him as saying, “We are bringing to the table a mass-market opportunity for the up-and-coming artist and, really, artists at every level and wrapping them with a support system that will boost them, help acquire and add to their fanbase and, more importantly, really monetize in the days of uncertainty when venues have been shut down for so long.” In addition, Fan Pass version 2.0 has “added new features and ways of developing revenue streams for the artists.” To view the full article, visit

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday's trading session at $0.0081, off by 2.4096%, on 7,553,510 volume with 71 trades. The average volume for the last 3 months is 7.554M and the stock's 52-week low/high is $0.00699/$0.097900003.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

recently conducted study has found that in comparison with low-grade gliomas, high-grade gliomas in canines contain more immune cells linked to suppressing immune response. The study adds to evidence suggesting that these tumors may recruit immune cells which assist with immunosuppression. Its findings may be useful in the development of future glioma treatments for both dogs and humans. In the meantime, companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working to develop superior remedies for the malignancies that impact the central nervous system as well as the brain.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.59, off by 0.625%, on 86,821 volume with 354 trades. The average volume for the last 3 months is 86,343 and the stock's 52-week low/high is $1.38999998/$4.46000003.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

  • Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced its entry into agreements with TruTrace Technologies Inc. (CSE: TTT) (OTCQB: TTTSF) and Applied DNA Sciences Inc. (NASDAQ: APDN) to launch a complete and differentiated global cannabis product validation and authentication platform for consumers, distributors and government regulators. The initiative further demonstrates Flora’s commitment to operational excellence and transparency enabling immutable genome-to-sale supply chain validation for domestic and international trading partners and government regulators. To view the full press release, visit
  • A recently published report that focused on the burgeoning CBD market estimates that by 2028, the global legal cannabis market will have reached $70.6 billion. Marijuana is one of the largest growth industries on the stock market. However, not all cannabis business segments are equal, with estimates showing that in the near future, some segments will considerably surpass others. One specific segment to watch is the CBD-infused products market. Various companies have joined the CBD-infused cosmetics market, including Valens Company Inc., which is involved in the sale of health as well as wellness products such as CBD bath bombs. Flora Growth Corp. (NASDAQ: FLGC) has also entered the market and offers a line of CBD wellness products.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $7.1, off by 12.0198%, on 1,730,675 volume with 9,936 trades. The average volume for the last 3 months is 1.731M and the stock's 52-week low/high is $2.8499999/$21.4500007.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading